Urinary connective tissue growth factor excretion in patients with type 1 diabetes and nephropathy

Diabetes Care

Volumn 26, Issue 9, 2003, Pages 2632-2636

  Gilbert, Richard E ^a   Akdeniz, Aysel ^b   Weitz, Stephen ^a   Usinger, William R ^a   Molineaux, Christopher ^a   Jones, Susan E ^a   Langham, Robyn G ^a   Jerums, George ^b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b FIBROGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CONNECTIVE TISSUE GROWTH FACTOR; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FOSINOPRIL; PERINDOPRIL;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE URINE LEVEL; DIABETIC NEPHROPATHY; DIAGNOSTIC VALUE; DISEASE MARKER; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INTERSTITIAL NEPHRITIS; KIDNEY INJURY; MALE; MICROALBUMINURIA; PATHOGENESIS; RELIABILITY; URINARY EXCRETION;

ADULT; ALBUMINURIA; BIOLOGICAL MARKERS; BLOOD PRESSURE; CREATININE; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MIDDLE AGED; TRANSFORMING GROWTH FACTOR BETA;

EID: 0041322515     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.26.9.2632     Document Type: Article

References (30)

1. Remuzzi G, Bertani T: Pathophysiology of progressive nephropathies. N Engl J Med 339:1448-1456, 1998
2. Wang SN, Hirschberg R: Growth factor ultrafiltration in experimental diabetic nephropathy contributes to interstitial fibrosis. Am J Physiol Renal Physiol 278:F554-F560, 2000
3. Ellis D, Forrest KY, Erbey J, Orchard TJ: Urinary measurement of transforming growth factor-beta and type IV collagen as new markers of renal injury: application in diabetic nephropathy. Clin Chem 44:950-956, 1998
4. Gilbert RE, Akdeniz A, Allen TJ, Jerums G: Urinary transforming growth factor-beta in patients with diabetic nephropathy: implications for the pathogenesis of tubulointerstitial pathology (Letter). Nephrol Dial Transplant 16:2442-2443, 2001
5. Agarwal R, Siva S, Dunn SR, Sharma K: Add-on angiotensin II receptor blockade lowers urinary transforming growth factor-beta levels. Am J Kidney Dis 39:486-492, 2002
6. Gupta S, Clarkson MR, Duggan J, Brady HR: Connective tissue growth factor: potential role in glomerulosclerosis and tubulointerstitial fibrosis. Kidney Int 58:1389-1399, 2000
7. Mogensen CE, Chachati A, Christensen CK, Close C, Deckert T, Hommel E, Kastrup J, Lefebvre P, Mathiesen E, Feldt-Rasmussen B, Schmitz A, Viberti GC: Microalbuminuria: an early marker of renal involvement in diabetes. Uremia Invest 9:85-95, 1985-1986
8. Jerums G, Allen TJ, Campbell DJ, Cooper ME, Gilbert RE, Hammond JJ, Raffaele J, Tsalamandris C: Long-term comparison between perindopril and nifedipine in normotensive patients with type 1 diabetes and microalbuminuria. Am J Kidney Dis 37:890-899, 2001
9. Houlihan CA, Akdeniz A, Tsalamandris C, Cooper ME, Jerums G, Gilbert RE: Urinary transforming growth factor-β excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction. Diabetes Care 25:1072-1077, 2002
10. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia): Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 349:1857-1863, 1997
11. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861-869, 2001
12. Nath KA: Tubulointerstitial changes as a major determinant in the progression of renal damage. Am J Kidney Dis 20:1-17, 1992
13. Gilbert RE, Cooper ME: The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury? Kidney Int 56:1627-1637, 1999
14. Newman DJ, Thakkar H, Gallagher H: Progressive renal disease: does the quality of the proteinuria matter or only the quantity? Clin Chim Acta 297:43-54, 2000
15. Wang SN, LaPage J, Hirschberg R: Role of glomerular ultrafiltration of growth factors in progressive interstitial fibrosis in diabetic nephropathy. Kidney Xidney Int 57:1002-1014, 2000
16. Wang S, Denichilo M, Brubaker C, Hirschberg R: Connective tissue growth factor in tubulointerstitial injury of diabetic nephropathy. Kidney Int 60:96-105, 2001
17. Kothapalli D, Frazier KS, Welply A, Segarini PR, Grotendorst GR: Transforming growth factor beta induces anchorage-independent growth of NRK fibroblasts via a connective tissue growth factor-dependent signaling pathway. Cell Growth Differ 8:61-68, 1997
18. Frazier K, Williams S, Kothapalli D, Klapper H, Grotendorst GR: Stimulation of fibroblast cell growth, matrix production, and granulation tissue formation by connective tissue growth factor. J Invest Dermatol 107:404-411, 1996
19. Kikuchi K, Kadono T, Ihn H, Sato S, Igarashi A, Nakagawa H, Tamaki K, Takehara K: Growth regulation in scleroderma fibroblasts: increased response to transforming growth factor-beta 1. J Invest Dermatol 105:128-132, 1995
20. Paradis V, Dargere D, Vidaud M, De Gouville AC, Huet S, Martinez V, Gauthier JM, Ba N, Sobesky R, Ratziu V, Bedossa P: Expression of connective tissue growth factor in experimental rat and human liver fibrosis. Hepatology 30:968-976, 1999
21. Allen JT, Knight RA, Bloor CA, Spiteri MA: Enhanced insulin-like growth factor binding protein-related protein 2 (connective tissue growth factor) expression in patients with idiopathic pulmonary fibrosis and pulmonary sarcoidosis. Am J Respir Cell Mol Biol 21:693-700, 1999
22. Ito Y, Aten J, Bende RJ, Oemar BS, Rabelink TJ, Weening JJ, Goldschmeding R: Expression of connective tissue growth factor in human renal fibrosis. Kidney Int 53:853-861, 1998
23. Wahab NA, Yevdokimova N, Weston BS, Roberts T, Li XJ, Brinkman H, Mason RM: Role of connective tissue growth factor in the pathogenesis of diabetic nephropathy. Biochem J 359:77-87, 2001
24. Riser BL, Denichilo M, Cortes P, Baker C, Grondin JM, Yee J, Narins RG: Regulation of connective tissue growth factor activity in cultured rat mesangial cells and its expression in experimental diabetic glomerulosclerosis. J Am Soc Nephrol 11:25-38, 2000
25. Wahab NA, Brinkman H, Mason RM: Uptake and intracellular transport of the connective tissue growth factor: a potential mode of action. Biochem J 359:89-97, 2001
26. Ueno M, Kawashima S, Nishi S, Shimada S, Shimada N, Karasawa R, Suzuki Y, Muruyama Y, Arakawa M: Tubulointerstitial lesions in non-insulin dependent diabetes mellitus. Kidney Int 52 (Suppl. 63):S191-S194, 1997
27. Hishikawa K, Oemar BS, Nakaki T: Static pressure regulates connective tissue growth factor expression in human mesangial cells. J Biol Chem 276:16797-16803, 2001
28. Mori T, Kawara S, Shinozaki M, Hayashi N, Kakinuma T, Igarashi A, Takigawa M, Nakanishi T, Takehara K: Role and interaction of connective tissue growth factor with transforming growth factor-beta in persistent fibrosis: a mouse fibrosis model. J Cell Physiol 181:153-159, 1999
29. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, for the Collaborative Study Group: The effect of angiotensin-convertingenzyme inhibition on diabetic nephropathy. N Engl J Med 329:1456-1462, 1993
30. Sharma K, Ziyadeh FN, Alzahabi B, McGowan TA, Kapoor S, Kurnik BRC, Kurnik PB, Weisberg LS: Increased renal production of transforming growth factor-β1 in patients with type II diabetes. Diabetes 46:854-859, 1997